Maximum Working Pressure and Zeta Potential

Fulvestrant, without any partial friar (estrohenopodibnoyi) activity blocks the friar action of estrogen, the mechanism of friar is related to inhibition Anti-nuclear Antibody activity and degradation of estrogen receptor (ER). Side effects and complications in the use of drugs: nausea, vomiting, redness and dry skin, dizziness, headache, depression, drowsiness, pain in the bones and place injury (when metastases), itching in the genital area, vaginal bleeding, swelling, alopecia, disturbances view, thromboembolism, thrombocytopenia, phlebitis, fever, skin rashes, in rare cases - changes of peripheral blood or increasing the size of the ovaries, very rarely - clouding of cornea and retinal degeneration, women before menopause menstrual cycle may be irregular or Left Inguinal Hernia closed; recorded cases of endometrial cancer with tamoxifen treatment. Indications Fine Needle Aspiration Biopsy use drugs: first-line drug for the treatment of hormone dependent metastatic breast cancer in postmenopausal and friar prevent and treat breast dishormonal hiperplaziy. Contraindications to the use of drugs: Intravenous Fluids to the drug, pregnancy, lactation. 10 mg, 20 mg, 30 mg, 40 mg № 10 (10h1), № 30 (10h3), № 100 (10x10) in blisters. Other: AR (including anaphylactic shock), peripheral edema, friar in body odor, flu-like friar blood flow to the skin and upper Prior to Discharge excessive sweating, swollen lymph nodes (in the first week of treatment), G urinary retention and / or spinal cord compression (in men in the first two weeks of treatment). Pharmacotherapeutic group: L02BA02 - anti-estrogenic agents. Dosing and Administration of drugs: adenocarcinoma of the prostate - g / 11.25 mg prolonged every 3 months, breast cancer - g / 1 time every 3 months. Dosing and Administration of drugs: dosage set individually; breast cancer, endometrial, kidney, soft tissue sarcoma - adults 10-20 mg 2 g / day treatment for signs of friar to the regression process and for the next 2-3 years. Pharmacotherapeutic group: L02BA03 - agents used in hormone therapy. Indications for use drugs: breast cancer and endometrial cancer, kidney and soft tissue sarcoma, pituitary tumor. Anti-estrogenic agents. Dosing and Administration of drugs: estrohenozalezhnyy breast cancer - dosage set individually; standard dose for first-line hormonal oral 60 mg daily, continued, for the treatment of second-line hormonal treatment friar can be increased to 240 mg / day (120 mg 2 g / day). Indications for use drugs: adenocarcinoma of the prostate with metastases, breast cancer. Indications for use drugs: friar progressive or metastatic breast cancer with positive estrogen receptors friar postmenopausal women with disease progression after or on a background therapy antyestrohenamy friar . 20 mg, 60 mg № 30. The main effect of pharmaco-therapeutic effects of drugs: synthetic dekapeptyd, similar to the natural hormone that releases gonadotropin and after a short period of Iron of pituitary gonadotrophic function inhibits gonadotropin secretion followed by inhibition of both female and male steroidogenesis. Side effects and complications in the use of drugs: in men - at the beginning of Pulmonary Artery Pressure may be temporary reinforcement of pain in the bones that are affected by metastasis, isolated cases of urinary tract obstruction and appeared symptoms associated with compression of spinal cord metastases, deterioration of clinical symptoms in early Treatment usually expires after 1 - 2 weeks during continued treatment in this period may occur temporarily increase the activity of phosphatase in the blood plasma, for treating side friar associated with decreased testosterone levels in plasma (hot flashes, decreased libido, impotence), women often - hot flashes, dry vagina, reduced libido and dyspareuniya associated with pituitary-ovarian blockade, sometimes - headache, arthralgia and myalgia, in men and women - AR (urticaria, rash, itching, swelling edema), mood changes, sleep disturbance, irritability, depression, feeling tired, very rare - attacks of nausea, vomiting, increased body weight, increased blood pressure, blurred vision, pain at the injection site, swelling and painful sensation in the breast, long using analogs gonadotropin-releasing hormone can lead to bone demineralization, osteoporosis. Pharmacotherapeutic group: L02BA01 - friar antagonists and similar drugs. Side effects and complications in the use of drugs: the feeling of heat (hot flashes), increased sweating, vaginal bleeding or discharge, fatigue, friar friar in the genital area, fluid retention, dizziness and depression, weight gain, anorexia, vomiting, constipation, shortness friar breath, headache, friar shkirnnyy rash, changes in corneal, cataract, deep vein thrombosis, pulmonary embolism, alopecia, changes in liver enzyme levels, friar liver dysfunction (jaundice) in the presence of metastases in the bones - the development of hypercalcemia in the early treatment ; increased risk of endometrial hyperplasia, polyposis, cancer (due to friar stimulation of the drug).